Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur® Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.
Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer / G. Aurilio, M.T. Sandri, G. Pruneri, L. Zorzino, E. Botteri, E. Munzone, L. Adamoli, G. Facchi, D. Cullurà, E. Verri, M.C. Rocca, S. Zurrida, R. Iacovelli, F. Nolè. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 12:17(2016), pp. 2001-2008. [10.2217/fon-2016-0081]
Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer
G. Pruneri;S. Zurrida;
2016
Abstract
Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur® Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Aurilio_Future Oncology_2016.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
